The latest analyst update on MDxHealth cuts fair value from about US$1.80 to roughly US$0.83 per share, which is a sizable reset in how the stock is being framed. This shift lines up with more cautious Street commentary after the preliminary Q3 2026 revenue shortfall and the suspension of 2026 revenue guidance, as well as renewed questions about growth visibility and liquidity. As you read on, you will see how this revised price target fits into the broader MDxHealth story and how to track...